Michael Petusky

Stock Analyst at Barrington Research

(2.26)
# 2,738
Out of 5,147 analysts
230
Total ratings
40.29%
Success rate
-1.98%
Average return

Stocks Rated by Michael Petusky

Anika Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $16$17
Current: $14.36
Upside: +18.38%
LeMaitre Vascular
Feb 26, 2026
Maintains: Outperform
Price Target: $95$105
Current: $108.18
Upside: -2.94%
Orthofix Medical
Feb 25, 2026
Maintains: Outperform
Price Target: $18$17
Current: $13.53
Upside: +25.65%
Merit Medical Systems
Feb 25, 2026
Maintains: Outperform
Price Target: $106$109
Current: $77.18
Upside: +41.23%
Henry Schein
Feb 25, 2026
Maintains: Outperform
Price Target: $79$97
Current: $82.39
Upside: +17.73%
U.S. Physical Therapy
Feb 20, 2026
Maintains: Outperform
Price Target: $103
Current: $82.96
Upside: +24.16%
Bioventus
Feb 9, 2026
Initiates: Outperform
Price Target: $13
Current: $8.78
Upside: +48.06%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $93$94
Current: $63.32
Upside: +48.45%
Option Care Health
Jan 16, 2026
Maintains: Outperform
Price Target: $38$42
Current: $32.46
Upside: +29.39%
VerifyMe
Jan 6, 2026
Maintains: Outperform
Price Target: $1$1.5
Current: $0.95
Upside: +57.40%
Maintains: Outperform
Price Target: $14
Current: $14.68
Upside: -4.63%
Maintains: Outperform
Price Target: $2.25
Current: $1.20
Upside: +87.50%
Downgrades: Market Perform
Price Target: n/a
Current: $7.20
Upside: -